QURE - uniQure sheds 30% after data for Huntington's disease candidate

2023-06-21 08:24:41 ET

Dutch biotech uniQure N.V. ( NASDAQ: QURE ) fell ~30% pre-market Wednesday after announcing interim data from its Phase 1/2 trial for AMT-130 in the treatment of neurogenerative disorder Huntington’s disease.

Citing up to 24 months of follow-up data from 26 patients, uniQure ( QURE ) said that in the cerebrospinal fluid (CSF) of those who received AMT-130, there was a temporary increase in Neurofilament Light Chain (NfL), a biomarker of neurodegeneration.

However, the company said the NfL increases were not dose-dependent, and CSF NfL levels declined in all patients subsequently.

The U.S.-based trial was designed to evaluate low and high doses of the one-time gene therapy in patients with early-manifest Huntington’s disease.

Efficacy data from the trial indicate that clinical function was maintained for 24 months and 12 months in patients in the low-dose and high-dose cohorts, respectively.

The study drug was generally well tolerated with a manageable safety profile across low and high-dose cohorts, uniQure ( QURE ) said.

The company expects to disclose additional clinical data from its U.S. and EU Phase 1/2 studies for AMT-130 in Q4 2023 before meeting regulators in Q1 2024 to discuss data.

For further details see: